XNYS · Healthcare Plans
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$410.95-0.80%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
60/100
Positive
Score components
TickerWhale View
Elevance Health scores 60 out of 100 overall, which we rate positive. Technical is its strongest area and Risk its weakest.
What helps
- Technical
- Quality & growth
What to watch
- Valuation
- Risk
- Sentiment Signal
Quality & growth
30%65Positive
- Revenue growth 6.3%
- EPS growth -4.3%
Valuation
25%40Weak
- P/E 18.0
- EV/Sales 0.5
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
#142 by market cap in our coverage · ~97,100 employees · Listed 2001-10-30 · www.elevancehealth.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#52 / 139sector rank by TickerWhale Score
TickerWhale Score 60 vs sector average 55.1 (+4.9)
Revenue growth (industry)Top 88%
Gross margin (industry)Top 25%
Return on equity (industry)Top 50%
P/E (industry)Cheaper than 83%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
87/100Strong vs universe
Ranks 87th of 100 covered names on our technical composite — the composite itself scores 69/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
3 buy · 1 sell · 4 neutral of 8 votes
TickerWhale rates ELV's technical setup strong — 87th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
7 / 9constructive
- vs 200-day+13.2%
- vs 50-day+3.5%
Momentum
Mixed
- RSI (14)54 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength15· weak trend
- MACD (12,26,9)buy(histogram 0.360)
How the classic verdict is reached
Moving averages (9) agree on buy — 7 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 1 sell · 4 neutral.
Result — 3 buy vs 1 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)18.0
- P/S (TTM)0.4
- P/B2.0
- EV/EBITDA—
- EV/Sales0.5
- PEG—
Profitability & returns
- Gross margin26.0%
- Net margin2.5%
- ROE11.2%
- Debt/Equity0.69
Growth
- Revenue growth (YoY)6.3%
- EPS growth (YoY)-4.3%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $89.5B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ELVCurrentElevance Health | 60 | 69 | 18.0 | — | 2.0 | 0.5 | $410.95 | -0.80% | +6.3% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.